Ultragenyx Pharmaceutical | RARE - EPS Earnings Per Share


Ultragenyx Pharmaceutical reported $-0.9 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 -1.04 -1.81 Nov/04
FY2026Q2 Jun/2026 -0.90 -1.23 -1.17 Aug/04
FY2026Q1 Mar/2026 -1.84 -1.43 -1.57 May/05
FY2025Q4 Dec/2025 -1.29 -1.17 -1.39 Feb/12
FY2025Q3 Sep/2025 -1.81 -1.23 -1.40 Nov/04




Eps Change Date
Acadia Pharmaceuticals USD 0.18 0.16 Jun/2026
Agios Pharmaceuticals USD -1.69 0 Jun/2026
Alnylam Pharmaceuticals USD 1.84 0.15 Jun/2026
BioCryst Pharmaceuticals USD 0.3 0.87 Jun/2026
BioMarin Pharmaceutical USD 0.76 0.3 Mar/2026
Immunic USD -0.1 0.03 Dec/2025
Insmed USD -0.76 0.78 Mar/2026
Ionis Pharmaceuticals USD -0.69 0.13 Jun/2026
Karyopharm Therapeutics USD -1.02 1.2 Mar/2026
Kyowa Hakko Kirin JPY 35.49 12.5 Jun/2026
MacroGenics USD -0.58 0.36 Mar/2026
Moderna USD -1.97 1.43 Jun/2026
Neurocrine Biosciences USD 2.85 0.91 Jun/2026
PTC Therapeutics USD 0.92 0.95 Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 14.29 4.82 Jun/2026
Sarepta Therapeutics USD 0.64 2.52 Jun/2026
Ultragenyx Pharmaceutical USD -0.9 0.94 Jun/2026
Vertex Pharmaceuticals USD 4.73 0.26 Jun/2026